Effects of neoadjuvant VEGF-TKI treatment on surgery for renal cell carcinoma: A systematic review and meta-analysis

被引:2
|
作者
Zhu, Meikai [1 ]
Liu, Zhifeng [2 ]
Zhou, Yongheng [1 ]
Jiang, Zhiwen [1 ]
Chen, Shouzhen [1 ]
Wang, Wenfu [1 ]
Shi, Benkang [1 ]
Zhu, Yaofeng [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Urol, 107 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China
[2] Taian City Cent Hosp, Dept Urol, Tai An 271000, Shandong, Peoples R China
关键词
neoadjuvant therapy; targeted therapy; renal cell carcinoma; surgical treatment; nephrectomy; TARGETED MOLECULAR THERAPIES; VENA-CAVA THROMBECTOMY; PARTIAL NEPHRECTOMY; TUMOR THROMBUS; SUNITINIB; SORAFENIB; AXITINIB; CANCER; TRIAL;
D O I
10.3892/ol.2024.14295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the effects of neoadjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) treatment on surgery in patients with renal cell carcinoma (RCC), sources from Embase, PubMed and the Cochrane Library databases collected from inception to December, 2022 were used for analysis in the present study, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data regarding surgical outcomes were collected. The pooled effect sizes were calculated in terms of the risk ratio (RR)/standard mean difference (SMD) with 95% confidence intervals (CIs) using the random-effects model. Subgroup and sensitivity analyses were used to explore the source of heterogeneity within the data. In total, 9 identified articles involving 829 patients (336 in the neoadjuvant + surgery group; 493 in the surgery group) were included in the present study, according to the criteria. The results demonstrated that there were no significant differences in blood loss (SMD=-0.11; 95% CI, -0.63-0.41; P=0.68), postoperative length of hospital stay or total length of hospital stay (SMD=0.23; 95% CI, -0.55-1.01; P=0.57) or complications (RR=1.16; 95% CI, 0.80-1.67; P=0.44) between the two groups. However, neoadjuvant therapy reduced the operation time (SMD=-0.67; 95% CI, -1.25- -0.09; P=0.02) and resulted in a greater proportion of patients choosing partial nephrectomy (RR=1.84; 95% CI, 1.47-2.31; P<0.00001). In the subgroup analysis, the blood loss was significantly lower in patients with RCC with inferior vena cava tumor thrombus in the neoadjuvant group (SMD=-1.10; 95% CI, -1.82- -0.38; P=0.003). In conclusion, the results of the present study indicated that neoadjuvant VEGF-TKI treatment in patients with RCC shortened operation time, decreased blood loss and did not cause an increase in perioperative complications. In addition, this treatment modality may encourage patients to opt for partial nephrectomy to preserve renal function.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis
    Wright, Bryan
    Johnson, Bradley S.
    Vassar, Matt
    Saidian, Ava
    Rais-Bahrami, Soroush
    Gunn, Andrew J.
    ABDOMINAL RADIOLOGY, 2022, 47 (06) : 2238 - 2243
  • [42] The association between statin administration and renal cell carcinoma; a systematic review and meta-analysis
    Ramezannezhad, Pantea
    Khosravifarsani, Mohammadreza
    JOURNAL OF RENAL INJURY PREVENTION, 2023, 12 (02):
  • [43] Eosinophilic Solid and Cystic Renal Cell Carcinoma-A Systematic Review and Meta-Analysis
    Loghin, Andrada
    Popelea, Maria Catalina
    Todea-Moga, Ciprian Doru
    Cocuz, Iuliu Gabriel
    Borda, Angela
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [44] Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review
    Bai, Yangyang
    Li, Songchao
    Jia, Zhankui
    Ding, Yinghui
    Gu, Chaohui
    Yang, Jinjian
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (02) : 79.e1 - 79.e10
  • [45] Microvascular invasion as a prognostic indicator in renal cell carcinoma: a systematic review and meta-analysis
    Huang, Hai
    Pan, Xiu-Wu
    Huang, Yi
    Xu, Dan-Feng
    Cui, Xin-Gang
    Li, Lin
    Hong, Yi
    Chen, Lu
    Gao, Yi
    Yin, Lei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (07): : 10779 - U3135
  • [46] Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis
    Dukkipati, Akasha
    Li, Xiaochen
    Pal, Sumanta K.
    Zugman, Miguel
    KIDNEY CANCER, 2023, 7 (01) : 147 - 159
  • [47] Combination Therapy for Metastatic Renal Cell Carcinoma A Systematic Review and Network Meta-analysis
    Alam, Muhammad U.
    Jazayeri, Seyed B.
    Gautam, Shiva
    Norez, Daniel
    Kumar, Jatinder
    Tanneru, Karthik
    Nguyen, Sabine
    Costa, Joseph
    Bandyk, Mark
    Ganapathi, Hariharan P.
    Koochekpour, Shahriar
    Balaji, K. C.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (07): : 477 - 483
  • [48] The role of sarcopenia in treatment-related outcomes in patients with renal cell carcinoma: A systematic review and meta-analysis
    Li Yuxuan
    Li Junchao
    Liu Wenya
    MEDICINE, 2022, 101 (43) : E31332
  • [49] First-line treatment in the management of advanced renal cell carcinoma: Systematic review and network meta-analysis
    Larkin, J.
    Paine, A.
    Foley, G.
    Mitchell, S. A.
    Chen, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S656 - S656
  • [50] First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis
    Larkin, James
    Paine, Abby
    Foley, Grace
    Mitchell, Stephen
    Chen, Connie
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (13) : 1915 - 1927